These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 15479756

  • 1. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study.
    Bongartz T, Coras B, Vogt T, Schölmerich J, Müller-Ladner U.
    Rheumatology (Oxford); 2005 Jan; 44(1):126-9. PubMed ID: 15479756
    [Abstract] [Full Text] [Related]

  • 2. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [Abstract] [Full Text] [Related]

  • 3. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study.
    Mazzotta A, Esposito M, Schipani C, Chimenti S.
    J Dermatolog Treat; 2009 Apr; 20(6):354-8. PubMed ID: 19954392
    [Abstract] [Full Text] [Related]

  • 4. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study.
    Voulgari PV, Venetsanopoulou AI, Exarchou SA, Alamanos Y, Tsifetaki N, Drosos AA.
    Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499
    [Abstract] [Full Text] [Related]

  • 5. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
    Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, IMPACT 2 Trial Investigators.
    Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
    [Abstract] [Full Text] [Related]

  • 6. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
    Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP.
    Arthritis Res Ther; 2004 Aug; 6(4):R326-34. PubMed ID: 15225368
    [Abstract] [Full Text] [Related]

  • 7. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
    Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E.
    Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
    [Abstract] [Full Text] [Related]

  • 8. Leflunomide in psoriatic arthritis.
    Kaltwasser JP.
    Autoimmun Rev; 2007 Sep; 6(8):511-4. PubMed ID: 17854740
    [Abstract] [Full Text] [Related]

  • 9. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F.
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A, Esposito M, Costanzo A, Chimenti S.
    Am J Clin Dermatol; 2009 Aug; 10(5):319-24. PubMed ID: 19658444
    [Abstract] [Full Text] [Related]

  • 11. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.
    Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, Landewé R, Steinfeld SD, Emery P, Dijkmans BA, Veale DJ.
    Ann Rheum Dis; 2005 Jun; 64(6):859-64. PubMed ID: 15528283
    [Abstract] [Full Text] [Related]

  • 12. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
    Gladman DD, ACCLAIM Study Investigators, Sampalis JS, Illouz O, Guérette B.
    J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284
    [Abstract] [Full Text] [Related]

  • 13. Subjective improvement in patients with psoriatic arthritis after short-term oral treatment with seal oil. A pilot study with double blind comparison to soy oil.
    Madland TM, Björkkjaer T, Brunborg LA, Fröyland L, Berstad A, Brun JG.
    J Rheumatol; 2006 Feb; 33(2):307-10. PubMed ID: 16465662
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
    Karanikolas GN, Koukli EM, Katsalira A, Arida A, Petrou D, Komninou E, Fragiadaki K, Zacharioudaki A, Lasithiotakis I, Giavri E, Vaiopoulos G, Sfikakis PP.
    J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
    [Abstract] [Full Text] [Related]

  • 15. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
    de Vlam K, Lories RJ.
    Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
    [Abstract] [Full Text] [Related]

  • 16. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study.
    McHugh NJ, Balachrishnan C, Jones SM.
    Rheumatology (Oxford); 2003 Jun; 42(6):778-83. PubMed ID: 12730539
    [Abstract] [Full Text] [Related]

  • 17. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices.
    Gottlieb AB, Mease PJ, Mark Jackson J, Eisen D, Amy Xia H, Asare C, Stevens SR.
    J Dermatolog Treat; 2006 Jun; 17(5):279-87. PubMed ID: 17092858
    [Abstract] [Full Text] [Related]

  • 18. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
    Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE.
    Brain; 2005 Jun; 128(Pt 6):1442-53. PubMed ID: 15817521
    [Abstract] [Full Text] [Related]

  • 19. Measurement of disease activity in psoriatic arthritis. Extended report.
    Ujfalussy I, Koó E.
    Z Rheumatol; 2003 Feb; 62(1):60-5. PubMed ID: 12624805
    [Abstract] [Full Text] [Related]

  • 20. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis.
    Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, Haas-Smith SA, Ritchlin CT.
    Ann Rheum Dis; 2008 Mar; 67(3):296-301. PubMed ID: 17967829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.